Longitudinal glaucoma treatment patterns with brinzolamide versus dorzolamide

M. T. Halpern, S. Sorensen, D. Covert, J. Hutton

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


We analysed retrospective US medical claims data to evaluate longitudinal usage patterns (modification of treatment over time) for glaucoma patients receiving the ophthalmic carbonic anhydrase inhibitors (CAIs) brinzolamide or dorzolamide. Patients enrolled in a healthcare plan at least 2 months before and 6 months after their first CAI pharmacy claim were eligible. Treatment failures, patients who switched off CAI and/or added concomitant glaucoma medications, were calculated at 1, 2, and 6 months. Six hundred and twenty-six patients met the inclusion criteria, 220 for brinzolamide and 406 for dorzolamide. Overall 6 months treatment failure rates were 49.1% and 53.2% for brinzolamide and dorzolamide, respectively. Six month failure rate due to discontinuing CAI only were 20.9% for brinzolamide and 24.6% for dorzolamide, while median days to treatment failure were 160 and 106, respectively (p=0.027). Evaluation of differences in longitudinal usage patterns for CAIs may be helpful in determining appropriate treatments for glaucoma patients.

Original languageEnglish (US)
Pages (from-to)111-120
Number of pages10
JournalJournal of medical economics
Issue number111-120
StatePublished - 2000
Externally publishedYes


  • Carbonic anhydrase inhibitors
  • Glaucoma
  • Resource utilisation
  • Retrospective analysis
  • Treatment failure

ASJC Scopus subject areas

  • Health Policy


Dive into the research topics of 'Longitudinal glaucoma treatment patterns with brinzolamide versus dorzolamide'. Together they form a unique fingerprint.

Cite this